Payment overview · 2025
General Payments
$500.13
25 reported records · 4 companies
Healthcare provider profile · identity verified
Huan A. Le, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · SAN DIEGO, CA · NPI 1780797381
Verified facts
What the public records show
CMS Open Payments records show Huan A. Le, M.D. received $500.13 in general payments during 2025 across 25 reported records.
AstraZeneca Pharmaceuticals LP accounted for 59.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 6 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Trelegy Ellipta.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 78 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 1079 claims for Trelegy Ellipta by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $296.75 | 59.3% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $155.51 | 31.1% | 21 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $30.49 | 6.1% | 2 | 2025 |
| Insmed, Inc. | Unresolved — no canonical attribution shown | $17.38 | 3.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $482.75 | 24 |
| Education | $17.38 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $296.75 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $296.75 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $89.71 | 14 | 2025 |
Source payment records
|
|||||
| NUCALA Normalized: nucala |
Biological | GlaxoSmithKline, LLC. | $65.80 | 7 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $30.49 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $30.49 | 2 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 1079 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
78 | 56 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
1079 | 227 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Montelukast Sodium | Montelukast Sodium | 5162 | 878 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 4440 | 837 |
| Famotidine | Famotidine | 3639 | 744 |
| Fluticasone Propionate | Fluticasone Propionate | 3429 | 627 |
| Prednisone | Prednisone | 1678 | 576 |
| Gabapentin | Gabapentin | 1492 | 285 |
| Baclofen | Baclofen | 1197 | 194 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 1159 | 213 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 1079 | 227 |
| Omeprazole | Omeprazole | 1021 | 190 |
| Escitalopram Oxalate | Escitalopram Oxalate | 1009 | 194 |
| Azelastine Hcl | Azelastine Hcl | 926 | 325 |
| Azithromycin | Azithromycin | 796 | 443 |
| Advair Hfa | Fluticasone Propion/Salmeterol | 638 | 199 |
| Trazodone Hcl | Trazodone Hcl | 613 | 107 |
| Sucralfate | Sucralfate | 578 | 117 |
| Duloxetine Hcl | Duloxetine Hcl | 576 | 99 |
| Nystatin | Nystatin | 509 | 120 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 500 | 323 |
| Diclofenac Sodium | Diclofenac Sodium | 442 | 167 |
| Alendronate Sodium | Alendronate Sodium | 384 | 69 |
| Breo Ellipta | Fluticasone/Vilanterol | 352 | 89 |
| Cefuroxime | Cefuroxime Axetil | 265 | 163 |
| Pantoprazole Sodium | Pantoprazole Sodium | 263 | 50 |
| Fluocinonide | Fluocinonide | 254 | 71 |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 244 | 38 |
| Tamsulosin Hcl | Tamsulosin Hcl | 217 | 43 |
| Quetiapine Fumarate | Quetiapine Fumarate | 216 | 35 |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 199 | 56 |
| Losartan Potassium | Losartan Potassium | 195 | 34 |
| Mirtazapine | Mirtazapine | 191 | 39 |
| Incruse Ellipta | Umeclidinium Bromide | 187 | 36 |
| Spiriva Respimat | Tiotropium Bromide | 173 | 36 |
| Atorvastatin Calcium | Atorvastatin Calcium | 167 | 28 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 163 | 53 |
| Breyna | Budesonide/Formoterol Fumarate | 160 | 43 |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 160 | 50 |
| Ventolin Hfa | Albuterol Sulfate | 151 | 48 |
| Buspirone Hcl | Buspirone Hcl | 148 | 24 |
| Dulera | Mometasone/Formoterol | 142 | 39 |
| Qvar Redihaler | Beclomethasone Dipropionate | 133 | 75 |
| Amlodipine Besylate | Amlodipine Besylate | 120 | 20 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 118 | 90 |
| Bupropion Hcl Sr | Bupropion Hcl | 117 | 31 |
| Meclizine Hcl | Meclizine Hcl | 115 | 29 |
| Memantine Hcl | Memantine Hcl | 114 | 25 |
| Advair Diskus | Fluticasone Propion/Salmeterol | 110 | 36 |
| Finasteride | Finasteride | 110 | 22 |
| Levofloxacin | Levofloxacin | 108 | 89 |
| Atrovent Hfa | Ipratropium Bromide | 96 | 16 |
| Oxybutynin Chloride | Oxybutynin Chloride | 92 | 23 |
| Doxycycline Hyclate | Doxycycline Hyclate | 91 | 59 |
| Ondansetron Odt | Ondansetron | 91 | 21 |
| Fluticasone-Salmeterol Hfa | Fluticasone Propion/Salmeterol | 88 | 66 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 84 | 36 |
| Linzess | Linaclotide | 81 | 19 |
| Symbicort | Budesonide/Formoterol Fumarate | 78 | 56 |
| Metformin Hcl | Metformin Hcl | 70 | 12 |
| Clobetasol Propionate | Clobetasol Propionate | 69 | 27 |
| Potassium Chloride | Potassium Chloride | 67 | 15 |
| Amoxicillin | Amoxicillin | 64 | 50 |
| Dicyclomine Hcl | Dicyclomine Hcl | 60 | 16 |
| Citalopram Hbr | Citalopram Hydrobromide | 59 | 11 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 59 | 11 |
| Megestrol Acetate | Megestrol Acetate | 56 | 14 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 54 | 14 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 54 | 18 |
| Celecoxib | Celecoxib | 53 | 17 |
| Carvedilol | Carvedilol | 52 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 52 | suppressed |
| Furosemide | Furosemide | 51 | 14 |
| Lidocaine | Lidocaine | 51 | 17 |
| Loperamide | Loperamide Hcl | 51 | 27 |
| Cephalexin | Cephalexin | 45 | 32 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 45 | 14 |
| Fluticasone-Vilanterol | Fluticasone/Vilanterol | 42 | 29 |
| Hydrocortisone | Hydrocortisone | 42 | 18 |
| Fluconazole | Fluconazole | 40 | 29 |
| Simvastatin | Simvastatin | 39 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 38 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 38 | suppressed |
| Metoprolol Succinate | Metoprolol Succinate | 37 | suppressed |
| Meloxicam | Meloxicam | 34 | 18 |
| Metoprolol Tartrate | Metoprolol Tartrate | 34 | suppressed |
| Eliquis | Apixaban | 32 | suppressed |
| Ketoconazole | Ketoconazole | 32 | 11 |
| Metoclopramide Hcl | Metoclopramide Hcl | 32 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 32 | 12 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 30 | 12 |
| Ondansetron Hcl | Ondansetron Hcl | 29 | 12 |
| Allopurinol | Allopurinol | 28 | suppressed |
| Alprazolam | Alprazolam | 28 | suppressed |
| Ciprofloxacin-Dexamethasone | Ciprofloxacin Hcl/Dexameth | 28 | 20 |
| Levalbuterol Tartrate Hfa | Levalbuterol Tartrate | 27 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 26 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 26 | suppressed |
| Lisinopril | Lisinopril | 26 | suppressed |
| Nitroglycerin | Nitroglycerin | 26 | suppressed |
| Fluticasone Propionate Hfa | Fluticasone Propionate | 25 | 17 |
| Lactulose | Lactulose | 25 | suppressed |
| Valsartan | Valsartan | 25 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 23 | 17 |
| Zolpidem Tartrate | Zolpidem Tartrate | 23 | suppressed |
| Tobramycin | Tobramycin | 22 | 16 |
| Ibuprofen | Ibuprofen | 21 | 16 |
| Januvia | Sitagliptin Phosphate | 20 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 20 | suppressed |
| Glipizide | Glipizide | 19 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 19 | suppressed |
| Sulindac | Sulindac | 19 | suppressed |
| Budesonide | Budesonide | 18 | suppressed |
| Methylprednisolone | Methylprednisolone | 18 | 17 |
| Theophylline Er | Theophylline Anhydrous | 18 | suppressed |
| Xiidra | Lifitegrast | 18 | suppressed |
| Atenolol | Atenolol | 17 | suppressed |
| Epinephrine | Epinephrine | 17 | 14 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 17 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 16 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 15 | suppressed |
| Lidocaine Hcl Viscous | Lidocaine Hcl | 14 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 14 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 14 | 14 |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 14 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 13 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 13 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 13 | suppressed |
| Enulose | Lactulose | 13 | suppressed |
| Fluocinolone Acetonide | Fluocinolone Acetonide | 13 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 13 | suppressed |
| Spironolactone | Spironolactone | 13 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 12 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 12 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 12 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 11 | suppressed |
| Proctozone-Hc | Hydrocortisone | 11 | suppressed |
| Tobramycin | Tobramycin In 0.225% Sod Chlor | 11 | suppressed |
| Tobramycin-Dexamethasone | Tobramycin/Dexamethasone | 11 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 11 | suppressed |
| Vascepa | Icosapent Ethyl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $500.13 · 25 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, BREZTRI, MOUNJARO, NUCALA, TRELEGY ELLIPTA, ZEPBOUND | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Trelegy Ellipta play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error